Webinar: antibody patents in Europe and beyond
06-08-2020
LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF
22-03-2018
Webinar: Plausibility differences determine patent variations in US and EU
28-09-2017
man_at_mouse / iStockphoto.com
When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch (BSKB).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
patenting antibodies, BSKB, patentability, 101, PTAB, antigen, Gerald Murphy, John Heithaus, US patents, antigen patents
